Aspire Biopharma Holdings, Inc.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net revenue | $6K | — | — | — | — |
| Cost of revenue | $6K | — | — | — | — |
| Gross margin | -$116 | — | — | — | — |
| General and administrative (including stock-based compensation of $14.1 million and $0, respectively) | $17.6M+1775.5% | $940K-29.8% | $1.3M+37.3% | $976K+3732.6% | $25K |
| Research and development | $924K+540.0% | $144K+100.4% | $72K | — | — |
| Sales and marketing | $790K+526.4% | $126K+218.1% | $40K | — | — |
| Total operating expenses | $19.4M+1498.1% | $1.2M+237.7% | $359K+136.7% | -$976K-3732.6% | -$25K |
| Loss from operations | -$19.4M-1498.1% | -$1.2M | — | — | — |
| Interest expense | -$8.5M-8606.4% | -$98K | — | — | — |
| Change in fair value of liabilities | $3.9M | — | — | — | — |
| Initial recognition of forward purchase liability | -$95K | — | — | — | — |
| Loss on extinguishment of debt | -$364K | — | — | — | — |
| Total other expense, net | -$5.1M-5134.9% | -$98K-101.7% | $5.8M+34.5% | $4.3M+0.0% | $4.3M |
| Loss before provision for income taxes | -$24.5M-1770.4% | -$1.3M-265.0% | -$359K | — | — |
| Income tax expense | -$1K | — | $481 | — | — |
| Net loss | -$24.5M-1768.9% | -$1.3M-129.3% | $4.5M+33.6% | $3.3M+13211.8% | -$25K |
| Weighted average shares outstanding of Common Stock, basic | 1.5M+116.7% | 690K-99.9% | 481.8M+1866.8% | 24.5M+0.0% | 24.5M |
| Weighted average shares outstanding of Common Stock, diluted | 1.5M+116.7% | 690K-99.9% | 481.8M+1866.8% | 24.5M+0.0% | 24.5M |
| Earnings Per Share, Diluted | -$16.38-762.1% | -$1.90-189900.0% | -$0.00-100.9% | $0.11+0.0% | $0.11 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
No Form 4 transactions on record.
Informational purposes only, not investment advice.